## George B Mcdonald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7459094/publications.pdf

Version: 2024-02-01

60 papers 8,355 citations

36 h-index 56 g-index

63 all docs 63
docs citations

63 times ranked

5968 citing authors

#	Article	IF	CITATIONS
1	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts. Annals of Internal Medicine, 2020, 172, 229.	3.9	157
2	Liver Complications Following Treatment of Hematologic Malignancy With Anti D22 alicheamicin (Inotuzumab Ozogamicin). Hepatology, 2019, 69, 831-844.	7.3	30
3	Cytomegalovirus hepatitis after bone marrow transplantation: An autopsy study with clinical, histologic and laboratory correlates. Journal of Viral Hepatitis, 2019, 26, 1344-1350.	2.0	6
4	Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood, 2017, 129, 2330-2332.	1.4	39
5	Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1257-1263.	2.0	29
6	How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood, 2016, 127, 1544-1550.	1.4	67
7	Decline in the Use of Surgical Biopsy for Diagnosis of Pulmonary Disease in Hematopoietic Cell Transplantation Recipients in an Era of Improved Diagnostics and Empirical Therapy. Biology of Blood and Marrow Transplantation, 2016, 22, 2243-2249.	2.0	20
8	Gastrointestinal Infections After Solid Organ or Hematopoietic Cell Transplantation. , 2016, , 311-332.		2
9	How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood, 2016, 128, 1449-1457.	1.4	27
10	Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. Lancet Haematology,the, 2016, 3, e516-e525.	4.6	10
11	Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood, 2015, 126, 113-120.	1.4	110
12	Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica, 2015, 100, 842-848.	3.5	75
13	Fibrosing Cholestatic Hepatitis C After Hematopoietic Cell Transplantation. American Journal of Surgical Pathology, 2015, 39, 212-220.	3.7	26
14	Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biology of Blood and Marrow Transplantation, 2015, 21, 1870-1882.	2.0	54
15	Urinary Elafin and Kidney Injury in Hematopoietic Cell Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 12-20.	4.5	28
16	Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review. Biology of Blood and Marrow Transplantation, 2014, 20, 1008-1013.	2.0	48
17	Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice. International Journal of Hematology, 2013, 97, 456-464.	1.6	37
18	Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes. Biology of Blood and Marrow Transplantation, 2013, 19, 1033-1039.	2.0	65

#	Article	IF	CITATIONS
19	A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 1323-1330.	2.0	76
20	Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2012, 18, 265-272.	2.0	59
21	Gastrointestinal, Hepatobiliary, Pancreatic, and Iron-Related Diseases in Long-Term Survivors of Allogeneic Hematopoietic Cell Transplantation. Seminars in Hematology, 2012, 49, 43-58.	3.4	29
22	Decreased Serum Albumin as a Biomarker for SevereÂAcute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1594-1601.	2.0	60
23	Hepatobiliary Complications of Hematopoietic Cell Transplantation, 40 Years On. Hepatology, 2010, 51, 1450-1460.	7.3	169
24	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2010, 363, 2091-2101.	27.0	1,335
25	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood, 2009, 113, 2888-2894.	1.4	115
26	A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood, 2007, 109, 4557-4563.	1.4	115
27	Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation. Expert Opinion on Investigational Drugs, 2007, 16, 1709-1724.	4.1	15
28	Advances in prevention and treatment of hepatic disorders following hematopoietic cell transplantation. Best Practice and Research in Clinical Haematology, 2006, 19, 341-352.	1.7	14
29	Gastrointestinal Graft-versus-Host Disease in Recipients of Autologous Hematopoietic Stem Cells: Incidence, Risk Factors, and Outcome. Biology of Blood and Marrow Transplantation, 2006, 12, 226-234.	2.0	92
30	An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood, 2006, 108, 749-755.	1.4	112
31	Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clinical Pharmacology and Therapeutics, 2005, 78, 298-308.	4.7	31
32	Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology, 2005, 41, 345-352.	7.3	65
33	Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood, 2004, 103, 78-84.	1.4	151
34	A silent epidemic in survivors of hematopoietic cell transplantation. Blood, 2004, 103, 1569-1569.	1.4	0
35	Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood, 2003, 101, 2043-2048.	1.4	323
36	Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease). Seminars in Liver Disease, 2002, 22, 027-042.	3.6	596

#	Article	IF	Citations
37	Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 2002, 99, 2310-2314.	1.4	235
38	Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. Blood, 2002, 99, 4245-4246.	1.4	40
39	Nutrient Support in Hematopoietic Cell Transplantation. Journal of Parenteral and Enteral Nutrition, 2001, 25, 219-228.	2.6	25
40	Expanding the use of transjugular intrahepatic portosystemic shunts for veno-occlusive disease. Liver Transplantation, 2001, 7, 154-157.	2.4	22
41	Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis. Hepatology, 2000, 32, 1265-1271.	7.3	114
42	Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10-year follow-up. Hepatology, 1999, 29, 1893-1899.	7.3	157
43	Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointestinal Endoscopy, 1999, 49, 612-621.	1.0	184
44	PERSISTENT NAUSEA AND ANOREXIA AFTER MARROW TRANSPLANTATION. Transplantation, 1998, 66, 1319-1324.	1.0	68
45	PREVENTION OF TRANSMISSION OF HEPATITIS C VIRUS IN BONE MARROW TRANSPLANTATION BY TREATING THE DONOR WITH??-INTERFERON1. Transplantation, 1996, 62, 1358-1360.	1.0	37
46	UTILITY OF TRANSVENOUS LIVER BIOPSIES AND WEDGED HEPATIC VENOUS PRESSURE MEASUREMENTS IN SIXTY MARROW TRANSPLANT RECIPIENTS. Transplantation, 1995, 59, 1015-1022.	1.0	144
47	ORAL BECLOMETHASONE DIPROPIONATE FOR TREATMENT OF HUMAN INTESTINAL GRAFT-VERSUS-HOST DISEASE. Transplantation, 1995, 60, 1231-1238.	1.0	30
48	Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology, 1994, 19, 1171-1181.	7.3	286
49	Etiology and outcome of diarrhea after marrow transplantation: A prospective study. Gastroenterology, 1994, 107, 1398-1407.	1.3	278
50	RECOGNITION AND RAPID DIAGNOSIS OF UPPER GASTROINTESTINAL CYTOMEGALOVIRUS INFECTION IN MARROW TRANSPLANT RECIPIENTS. Transplantation, 1994, 57, 231-237.	1.0	59
51	Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology, 1994, 19, 1171-1181.	7.3	12
52	A phase I/II study of prostaglandin E1for the prevention of hepatic venocclusive disease after bone marrow transplantation. British Journal of Haematology, 1993, 84, 724-730.	2.5	84
53	Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients. Annals of Internal Medicine, 1993, 118, 255.	3.9	1,070
54	A pilot study of lowâ€dose cyclosporin for graftâ€versusâ€host prophylaxis in marrow transplantation. British Journal of Haematology, 1992, 80, 49-54.	2.5	35

#	Article	IF	CITATIONS
55	A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology, 1988, 8, 463-470.	7.3	174
56	Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors. Hepatology, 1984, 4, 116-122.	7.3	817
57	Marrow transplantation in hepatitis-associated aplastic anemia. American Journal of Hematology, 1984, 17, 269-278.	4.1	35
58	The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: A prospective study of thirteen patients. Gastroenterology, 1980, 78, 764-771.	1.3	234
59	Gastrointestinal and Hepatic Manifestations of Chronic Graft versus Host Disease., 0,, 216-228.		5
60	Gastrointestinal and Hepatic Complications. , 0, , 1434-1455.		18